Bisphosphonates for RSD and bone density changes

Reflex Sympathetic Dystrophy (RSD), now commonly called Complex Regional Pain Syndrome (CRPS), can affect nerves, skin, blood flow, movement and bone. In an affected hand, foot, arm or leg, imaging may show reduced mineral density or a patchy, “washed-out” appearance. These findings can be alarming, but they are one part of a wider clinical picture rather than proof of the condition by themselves.

Bisphosphonates are medicines that slow the breakdown of bone. Researchers have investigated whether this effect, along with possible actions on inflammatory pain pathways, may help some people with CRPS. The treatment is not suitable for everyone, and Australian patients generally need assessment by a GP and a relevant specialist before it is considered.

Why RSD can affect bone

Reduced use of a painful limb can lead to disuse osteopenia, while changes in circulation and local inflammation may also influence bone turnover. A bone scan or X-ray might show regional abnormalities, particularly in the early stages of CRPS. These changes do not necessarily mean that the whole skeleton is becoming fragile in the same way as it can with widespread osteoporosis.

Symptoms often include burning or disproportionate pain, sensitivity to light touch, swelling, altered sweating, skin colour changes and stiffness. Some people notice temperature differences between limbs or changes in hair and nail growth. A clinician may use the Budapest criteria, medical history and physical examination rather than relying on a scan alone.

Several other conditions can resemble CRPS, including infection, nerve compression, inflammatory arthritis and vascular problems. Reviewing conditions that mimic CRPS can help explain why a careful differential diagnosis matters before starting a bone-targeted medicine.

How bisphosphonates may help

Medicines in this group include alendronate, pamidronate, zoledronic acid and, in some countries, neridronate. They attach to bone and reduce the activity of osteoclasts, the cells responsible for bone resorption. This may be relevant when imaging and symptoms suggest increased local bone turnover.

The pain-relieving effect may involve more than bone density. Bisphosphonates could influence inflammatory chemicals and pain signalling, although the exact mechanism in CRPS remains uncertain. They are not a general anaesthetic, nerve repair treatment or guaranteed way to reverse long-standing changes.

Treatment may be given by mouth or through an intravenous infusion, depending on the medicine and the specialist’s reasoning. Intravenous options require appropriate monitoring and access to a service that can manage infusion reactions. A clinician may also consider the duration of symptoms, bone findings, kidney function and previous treatments.

What the research shows

Clinical studies have reported pain and function improvements for some people with CRPS, particularly in selected cases with recent onset and evidence of regional bone loss. However, studies have often been small, used different drugs and schedules, or followed patients for limited periods. Results should therefore be viewed as promising but not definitive.

A specialist may discuss bisphosphonates when standard measures have not provided enough relief, or when bone turnover appears especially relevant. The decision should be individual rather than based on an X-ray result alone. General health research information can provide background, but it cannot replace advice based on a person’s medical history.

In Australia, availability can vary between public hospitals, private specialists and local pharmacies. Some uses may be outside the medicine’s standard approved indications, and Pharmaceutical Benefits Scheme coverage cannot be assumed. A patient in Brisbane, Perth or regional New South Wales may also face different referral times and access to infusion services.

Safety checks and possible side effects

Common short-term effects can include flu-like symptoms, fever, muscle aches, headache or temporary worsening of pain after an infusion. Oral medicines may irritate the oesophagus and stomach if they are not taken exactly as directed. Dental concerns, low calcium levels and kidney problems also need attention before treatment.

Rare but serious complications include osteonecrosis of the jaw and unusual fractures of the thigh bone, especially with prolonged exposure or particular risk factors. Kidney function and calcium levels may need checking, and a dental review can be sensible when invasive dental work is planned. People should tell their doctor about pregnancy, kidney disease, low vitamin D, swallowing problems and current medicines.

A GP, rheumatologist, pain physician or endocrinologist can weigh likely benefits against risks. Patients should not buy or borrow bisphosphonates, change doses or arrange infusions without supervision. Severe muscle cramps, breathing difficulty, facial swelling, chest pain or a serious allergic reaction require urgent medical attention.

Monitoring treatment and progress

Before treatment, assessment may include a physical examination, blood tests, kidney function, calcium and vitamin D measurements. Depending on symptoms, a doctor may request X-rays, a bone scan or a bone density scan. These tests answer different questions: a DEXA scan measures bone mineral density, while a bone scan can show patterns of activity.

Pain scores can be useful, but progress should also be judged by walking, gripping, sleep, work, dressing and tolerance of touch. Improvements may be gradual and may not appear as a dramatic change on imaging. A treatment plan should include a review date and clear reasons to continue, pause or stop.

Australian patients may receive follow-up through a hospital pain service, a community GP or a private clinic. Keeping a brief symptom diary can help when appointments are separated by several weeks, especially for people travelling from rural or remote areas to a larger centre such as Adelaide, Melbourne or Sydney.

Combining medicine with rehabilitation

Bisphosphonates are generally considered alongside rehabilitation rather than as a replacement for it. Graded movement, desensitisation, occupational therapy and physiotherapy can help restore confidence and function. The pace needs to be tailored because forcing an acutely painful limb may increase distress and reduce participation.

A multidisciplinary plan may also include sleep support, psychological therapy, education about pain processing and other medicines. The aim is to make useful activity possible while reducing fear, guarding and deconditioning. Some people benefit from hydrotherapy or carefully supervised exercises that feel more manageable than weight-bearing movement.

Long-term pain can affect employment, relationships and mood. Information from the RSD information hub may help families understand the condition, but personal treatment decisions still belong with a qualified healthcare professional. Speaking openly about anxiety, low mood or isolation is part of appropriate care, not a suggestion that the pain is imagined.

If you have RSD or CRPS with suspected bone density changes, arrange a review with your GP and ask whether referral to a pain, rheumatology or endocrinology service is appropriate. Bring your scan reports, medication list, dental history and a record of how symptoms affect daily activities so the discussion about bisphosphonates is informed and specific.